Clinical outcomes in phase 1 study of EBC-129, a first-in-class, anti–N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with gastroesophageal adenocarcinomas.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Wei-Peng Yong, Matthew C. H. Ng, Sunnie S. Kim, Funda Meric-Bernstam, Venkateshan Srirangam Prativadibhayankaram, Inderjeet Singh, Julienne Cometa, Stephanie Blanchard, Ranjani Nellore, Kunal J. Shah, Yock-Ann Lee, Chek Shik Lim, Bong Hwa Gan, Nurul Rozaini, Nur Quraishah Adanani, Joe Yeong, Veronica Diermayr
Institutions: National University Cancer Institute, Singapore, National Cancer Centre Singapore, University of Colorado Hospital, The University of Texas MD Anderson Cancer Center, Experimental Drug Development Centre, Agency for Science, Technology and Research, Institute of Molecular and Cell Biology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Research Foundation
OpenAlex ID: W7162496068
Cites:
Cited by:
Related to: